A citation-based method for searching scientific literature

List of co-cited articles
170 articles co-cited >1

Times Cited
  Times     Co-cited

A phase 3 trial of bevacizumab in ovarian cancer.
Timothy J Perren, Ann Marie Swart, Jacobus Pfisterer, Jonathan A Ledermann, Eric Pujade-Lauraine, Gunnar Kristensen, Mark S Carey, Philip Beale, Andrés Cervantes, Christian Kurzeder,[...]. N Engl J Med 2011

Incorporation of bevacizumab in the primary treatment of ovarian cancer.
Robert A Burger, Mark F Brady, Michael A Bookman, Gini F Fleming, Bradley J Monk, Helen Huang, Robert S Mannel, Howard D Homesley, Jeffrey Fowler, Benjamin E Greer,[...]. N Engl J Med 2011

OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.
Carol Aghajanian, Stephanie V Blank, Barbara A Goff, Patricia L Judson, Michael G Teneriello, Amreen Husain, Mika A Sovak, Jing Yi, Lawrence R Nycum. J Clin Oncol 2012

Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
Eric Pujade-Lauraine, Felix Hilpert, Béatrice Weber, Alexander Reuss, Andres Poveda, Gunnar Kristensen, Roberto Sorio, Ignace Vergote, Petronella Witteveen, Aristotelis Bamias,[...]. J Clin Oncol 2014

Independent radiologic review: bevacizumab in combination with gemcitabine and carboplatin in recurrent ovarian cancer.
Carol Aghajanian, Barbara Goff, Lawrence R Nycum, Yan Wang, Amreen Husain, Stephanie Blank. Gynecol Oncol 2014

Incorporation of pazopanib in maintenance therapy of ovarian cancer.
Andreas du Bois, Anne Floquet, Jae-Weon Kim, Joern Rau, Josep M del Campo, Michael Friedlander, Sandro Pignata, Keiichi Fujiwara, Ignace Vergote, Nicoletta Colombo,[...]. J Clin Oncol 2014

Independent radiologic review of AURELIA, a phase 3 trial of bevacizumab plus chemotherapy for platinum-resistant recurrent ovarian cancer.
Amreen Husain, Yan Wang, Lars C Hanker, Belén Ojeda, Maarit Anttila, Enrico Breda, Peter Vuylsteke, Eric Pujade-Lauraine. Gynecol Oncol 2016

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
Deborah K Armstrong, Brian Bundy, Lari Wenzel, Helen Q Huang, Rebecca Baergen, Shashikant Lele, Larry J Copeland, Joan L Walker, Robert A Burger. N Engl J Med 2006

Blinded independent central review of progression in cancer clinical trials: results from a meta-analysis.
O Amit, F Mannino, A M Stone, W Bushnell, J Denne, J Helterbrand, H U Burger. Eur J Cancer 2011

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.
P Therasse, S G Arbuck, E A Eisenhauer, J Wanders, R S Kaplan, L Rubinstein, J Verweij, M Van Glabbeke, A T van Oosterom, M C Christian,[...]. J Natl Cancer Inst 2000

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
E A Eisenhauer, P Therasse, J Bogaerts, L H Schwartz, D Sargent, R Ford, J Dancey, S Arbuck, S Gwyther, M Mooney,[...]. Eur J Cancer 2009

Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study.
Robert A Burger, Mark F Brady, Michael A Bookman, Bradley J Monk, Joan L Walker, Howard D Homesley, Jeffrey Fowler, Benjamin E Greer, Matthew Boente, Gini F Fleming,[...]. J Clin Oncol 2014

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.
Stephen A Cannistra, Ursula A Matulonis, Richard T Penson, Julie Hambleton, Jakob Dupont, Howard Mackey, Jeffrey Douglas, Robert A Burger, Deborah Armstrong, Robert Wenham,[...]. J Clin Oncol 2007

Progression-free survival by local investigator versus independent central review: comparative analysis of the AGO-OVAR16 Trial.
Anne Floquet, Ignace Vergote, Nicoletta Colombo, Bent Fiane, Bradley J Monk, Alexander Reinthaller, Paula Calvert, Thomas J Herzog, Werner Meier, Jae-Weon Kim,[...]. Gynecol Oncol 2015

Maintenance treatment with interferon for advanced ovarian cancer: results of the Northern and Yorkshire gynaecology group randomised phase III study.
G D Hall, J M Brown, R E Coleman, M Stead, K S Metcalf, K R Peel, C Poole, M Crawford, B Hancock, P J Selby,[...]. Br J Cancer 2004

Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study.
Sabino De Placido, Giovanni Scambia, Giovanni Di Vagno, Emanuele Naglieri, Alessandra Vernaglia Lombardi, Rosalbino Biamonte, Marco Marinaccio, Giacomo Cartenì, Luigi Manzione, Antonio Febbraro,[...]. J Clin Oncol 2004

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.
Robert F Ozols, Brian N Bundy, Benjamin E Greer, Jeffrey M Fowler, Daniel Clarke-Pearson, Robert A Burger, Robert S Mannel, Koen DeGeest, Ellen M Hartenbach, Rebecca Baergen. J Clin Oncol 2003

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.
Alan Sandler, Robert Gray, Michael C Perry, Julie Brahmer, Joan H Schiller, Afshin Dowlati, Rogerio Lilenbaum, David H Johnson. N Engl J Med 2006

Recommendations for the assessment of progression in randomised cancer treatment trials.
J E Dancey, L E Dodd, R Ford, R Kaplan, M Mooney, L Rubinstein, L H Schwartz, L Shankar, P Therasse. Eur J Cancer 2009

Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a Gynecologic Oncology Group Study.
Bradley J Monk, Helen Q Huang, Robert A Burger, Robert S Mannel, Howard D Homesley, Jeffrey Fowler, Benjamin E Greer, Matthew Boente, Sharon X Liang, Lari Wenzel. Gynecol Oncol 2013

Measurements of adiposity as clinical biomarkers for first-line bevacizumab-based chemotherapy in epithelial ovarian cancer.
Katrina N Slaughter, Theresa Thai, Shayla Penaroza, Doris M Benbrook, Elangovan Thavathiru, Kai Ding, Tina Nelson, D Scott McMeekin, Kathleen N Moore. Gynecol Oncol 2014

Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer.
Martin R Stockler, Felix Hilpert, Michael Friedlander, Madeleine T King, Lari Wenzel, Chee Khoon Lee, Florence Joly, Nikolaus de Gregorio, José Angel Arranz, Mansoor Raza Mirza,[...]. J Clin Oncol 2014

Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial.
Dan Stark, Matthew Nankivell, Eric Pujade-Lauraine, Gunnar Kristensen, Lorraine Elit, Martin Stockler, Felix Hilpert, Andrés Cervantes, Julia Brown, Anne Lanceley,[...]. Lancet Oncol 2013

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.
Joyce F Liu, William T Barry, Michael Birrer, Jung-Min Lee, Ronald J Buckanovich, Gini F Fleming, Bj Rimel, Mary K Buss, Sreenivasa Nattam, Jean Hurteau,[...]. Lancet Oncol 2014

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.
Amit M Oza, Adrian D Cook, Jacobus Pfisterer, Andrew Embleton, Jonathan A Ledermann, Eric Pujade-Lauraine, Gunnar Kristensen, Mark S Carey, Philip Beale, Andrés Cervantes,[...]. Lancet Oncol 2015

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Kathleen Moore, Nicoletta Colombo, Giovanni Scambia, Byoung-Gie Kim, Ana Oaknin, Michael Friedlander, Alla Lisyanskaya, Anne Floquet, Alexandra Leary, Gabe S Sonke,[...]. N Engl J Med 2018

Randomized trial of adjuvant intraperitoneal alpha-interferon in stage III ovarian cancer patients who have no evidence of disease after primary surgery and chemotherapy: An intergroup study.
David S Alberts, Edward V Hannigan, Ping-Yu Liu, Caroline Jiang, Sharon Wilczynski, Larry Copeland, Maurie Markman. Gynecol Oncol 2006

Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer.
Jonathan Berek, Peyton Taylor, William McGuire, L Mary Smith, Birgit Schultes, Christopher F Nicodemus. J Clin Oncol 2009

Epidoxorubicin versus no treatment as consolidation therapy in advanced ovarian cancer: results from a phase II study.
G Bolis, S Danese, S Tateo, E Rabaiotti, G D'Agostino, C Merisio, G Scarfone, G Polverino, F Parazzini. Int J Gynecol Cancer 2006

Intraperitoneal radioactive phosphorus (32P) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: a randomized trial of the Gynecologic Oncology Group.
Mahesh A Varia, Frederick B Stehman, Brian N Bundy, Jo Ann Benda, Daniel L Clarke-Pearson, Ronald D Alvarez, Harry J Long. J Clin Oncol 2003

Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.
Jacobus Pfisterer, Béatrice Weber, Alexander Reuss, Rainer Kimmig, Andreas du Bois, Uwe Wagner, Hugues Bourgeois, Werner Meier, Serban Costa, Jens-Uwe Blohmer,[...]. J Natl Cancer Inst 2006

Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial.
Noriyuki Katsumata, Makoto Yasuda, Fumiaki Takahashi, Seiji Isonishi, Toshiko Jobo, Daisuke Aoki, Hiroshi Tsuda, Toru Sugiyama, Shoji Kodama, Eizo Kimura,[...]. Lancet 2009

Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.
Eric Pujade-Lauraine, Uwe Wagner, Elisabeth Aavall-Lundqvist, Val Gebski, Mark Heywood, Paul A Vasey, Birgit Volgger, Ignace Vergote, Sandro Pignata, Annamaria Ferrero,[...]. J Clin Oncol 2010

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.
Kathy Miller, Molin Wang, Julie Gralow, Maura Dickler, Melody Cobleigh, Edith A Perez, Tamara Shenkier, David Cella, Nancy E Davidson. N Engl J Med 2007

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Herbert Hurwitz, Louis Fehrenbacher, William Novotny, Thomas Cartwright, John Hainsworth, William Heim, Jordan Berlin, Ari Baron, Susan Griffing, Eric Holmgren,[...]. N Engl J Med 2004

RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer.
Nicholas J Robert, Véronique Diéras, John Glaspy, Adam M Brufsky, Igor Bondarenko, Oleg N Lipatov, Edith A Perez, Denise A Yardley, Stephen Y T Chan, Xian Zhou,[...]. J Clin Oncol 2011

Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.
Bradley J Monk, Thomas J Herzog, Stanley B Kaye, Carolyn N Krasner, Jan B Vermorken, Franco M Muggia, Eric Pujade-Lauraine, Alla S Lisyanskaya, Anatoly N Makhson, Janusz Rolski,[...]. J Clin Oncol 2010

Lessons learned from independent central review.
R Ford, L Schwartz, J Dancey, L E Dodd, E A Eisenhauer, S Gwyther, L Rubinstein, D Sargent, L Shankar, P Therasse,[...]. Eur J Cancer 2009

Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense?
Lori E Dodd, Edward L Korn, Boris Freidlin, C Carl Jaffe, Lawrence V Rubinstein, Janet Dancey, Margaret M Mooney. J Clin Oncol 2008

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.
Bernard Escudier, Anna Pluzanska, Piotr Koralewski, Alain Ravaud, Sergio Bracarda, Cezary Szczylik, Christine Chevreau, Marek Filipek, Bohuslav Melichar, Emilio Bajetta,[...]. Lancet 2007

The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab.
M P Smerdel, K D Steffensen, M Waldstrøm, I Brandslund, A Jakobsen. Gynecol Oncol 2010

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer.
Napoleone Ferrara, Kenneth J Hillan, Hans-Peter Gerber, William Novotny. Nat Rev Drug Discov 2004

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.
Jaafar Bennouna, Javier Sastre, Dirk Arnold, Pia Österlund, Richard Greil, Eric Van Cutsem, Roger von Moos, Jose Maria Viéitez, Olivier Bouché, Christophe Borg,[...]. Lancet Oncol 2013

Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial.
Noriyuki Katsumata, Makoto Yasuda, Seiji Isonishi, Fumiaki Takahashi, Hirofumi Michimae, Eizo Kimura, Daisuke Aoki, Toshiko Jobo, Shoji Kodama, Fumitoshi Terauchi,[...]. Lancet Oncol 2013

Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.
Ignace Vergote, Claes G Tropé, Frédéric Amant, Gunnar B Kristensen, Tom Ehlen, Nick Johnson, René H M Verheijen, Maria E L van der Burg, Angel J Lacave, Pierluigi Benedetti Panici,[...]. N Engl J Med 2010

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.
Robert A Burger, Michael W Sill, Bradley J Monk, Benjamin E Greer, Joel I Sorosky. J Clin Oncol 2007

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.
José Baselga, Javier Cortés, Sung-Bae Kim, Seock-Ah Im, Roberto Hegg, Young-Hyuck Im, Laslo Roman, José Luiz Pedrini, Tadeusz Pienkowski, Adam Knott,[...]. N Engl J Med 2012

Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.